CSL

Carlisle Companies Incorporated
$327.46
+7.89 (+2.47%)
Mkt Cap 13.19B
Volume 179,143
52W Range 293.43-432.91
Sector Basic Materials
Beta 0.83
EPS (TTM) 17.52 USD
P/E Ratio 18.61
Revenue (TTM) 5.10B USD
Rev Growth (5Y) +4.8%
EPS Growth (5Y) +24.2%
AlphaVal · Fair Value
What we estimate one share is worth
$308.16
Overvalued weak signal
5.8% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B+
Cyclical & Capital-Intensive
78.2 / 100 composite
A capital-heavy business that swings with its cycle — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 5.02B 5.00B 4.59B 5.45B 3.84B 3.97B 4.48B 4.48B 3.75B 3.43B 3.54B 3.20B
Net Income 740.70M 1.31B 767.40M 924.00M 421.70M 320.10M 472.80M 611.10M 365.50M 250.10M 319.70M 251.30M
EPS 17.27 28.26 15.35 17.80 8.01 5.85 8.28 10.09 5.75 3.86 4.89 3.89
Free Cash Flow 970.60M 945.80M 1.07B 817.40M 292.00M 604.80M 614.20M 218.50M 298.80M 422.40M 457.10M 177.10M
FCF / Share 22.68 20.34 21.35 15.78 5.56 11.10 10.79 3.62 4.74 6.58 7.05 2.76
Operating CF 1.10B 1.06B 1.21B 1.00B 426.80M 700.30M 703.10M 339.20M 458.70M 531.20M 529.20M 295.90M
Total Assets 6.26B 5.82B 6.62B 7.22B 7.25B 5.87B 5.50B 5.25B 5.30B 3.97B 3.95B 3.76B
Total Debt 2.88B 1.99B 2.32B 2.62B 2.99B 2.13B 1.65B 1.59B 1.59B 596.40M 745.50M 749.80M
Cash & Equiv 1.11B 753.50M 576.70M 364.80M 324.40M 897.10M 351.20M 803.60M 378.30M 385.30M 410.70M 730.80M
Book Value 1.80B 2.46B 2.83B 3.02B 2.63B 2.54B 2.64B 2.60B 2.53B 2.47B 2.35B 2.21B
Return on Equity 0.41 0.53 0.27 0.31 0.16 0.13 0.18 0.24 0.14 0.10 0.14 0.11
CSL News
Carlisle Exhibits Strong Prospects Despite Persisting Headwinds
Oct 09, 2026 07:31 AM · zacks.com
CX Institutional Sells 30,943 Shares of Carlisle Companies Incorporated $CSL
Oct 05, 2026 11:21 PM · defenseworld.net
Carlisle Companies Incorporated $CSL Stock Bought by MassMutual Private Wealth & Trust FSB
Oct 05, 2026 03:05 AM · defenseworld.net
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
Oct 04, 2026 02:18 PM · reuters.com
SSUMY or CSL: Which Is the Better Value Stock Right Now?
Sep 28, 2026 08:41 AM · zacks.com
Best Dividend Kings: September 2026
Sep 26, 2026 03:45 AM · seekingalpha.com
10 Dividend Growth Stocks: September 2026
Sep 24, 2026 07:31 PM · seekingalpha.com
The Dividend Kings Ranked By Quality Scores (September 2026)
Sep 18, 2026 04:16 AM · seekingalpha.com
Here's Why Carlisle (CSL) is a Strong Value Stock
Sep 15, 2026 06:41 AM · zacks.com
Carlisle Benefits From Business Strength, Risks Persist
Sep 10, 2026 09:30 AM · zacks.com